340B Cuts Could Impact Access to Specialty Drugs

For more than 25 years, the 340B Drug Pricing Program1 has helped safety-net facilities ...

Top Takeaways from this Year’s CBI Coupon & Copay Forum

At CBI’s eighth annual Coupon & Copay Forum in October, industry experts gathered virtually ...

First Fill Buy Downs: Maximizing Return in the Face of Prior Authorization

There is no question that prior authorization (PA) requirements around prescribed branded and specialty ...

The Unintended Consequences Behind Gilead’s Remdesivir Pricing Announcement

At the end of June, Gilead announced its long-awaited pricing strategy for remdesivir, which ...

The Ever-Evolving Remote Patient Monitoring Reimbursement Landscape

The urgency of the COVID-19 pandemic has illustrated how essential telehealth services are to ...

Value-Based Healthcare—Demonstrating Value in an Era of Increased Scrutiny and Accountability

Value-based care, value-based contracting, outcomes-based contracting, risk-based contracting—the emergence of these strategies have left ...